The FRY Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population offering targeted disruption of the FRY gene in Raji B lymphocytes. This heterogeneous pool enables loss-of-function studies without clonal selection, maintaining a mixed editing background suited for functional screening and pathway analysis where averaging across alleles is desirable.
The Raji cell line originates from an EBV-positive Burkitt lymphoma and harbors the hallmark MYC-IGH translocation. These B lymphocytes retain key immune functions such as antigen presentation and cytokine secretion, while exhibiting rapid proliferation. Widely used in lymphoma and immunology research, Raji provides a defined genetic and cancer-relevant context for gene editing.
FRY encodes a scaffold protein that integrates Hippo and STRIPAK signaling to regulate mitotic spindle orientation, cell polarity, and actin organization. Phosphorylated by CDK1 and Aurora A, FRY acts downstream of MST1/2 kinases and directly binds STRIPAK components like STRN3 and PP2A, modulating NDR1/2 kinases. This positions the dynein-dynactin motor at the cell cortex via NuMA, ensuring proper astral microtubule attachment. FRY also influences YAP/TAZ transcriptional co-activators, linking spindle mechanics to gene expression.
Knocking out FRY in Raji cells disrupts spindle orientation control, likely impairing mitotic fidelity and altering proliferation due to the MYC-driven background. Impaired YAP/TAZ regulation may further affect B-cell transcription programs, including those governing activation and antibody production. Given FRY’s tumor suppressor properties, this model is instrumental for dissecting Hippo pathway dysregulation in lymphoma, where EBV and MYC contribute to oncogenic signaling.
Applications include Western blotting for knockout validation, immunofluorescence for spindle and YAP/TAZ localization, and flow cytometry for cell cycle/apoptosis profiling. Co-immunoprecipitation reveals altered interactomes, and RNA-seq captures transcriptional responses. Drug sensitivity assays test Hippo inhibitor candidates. For further information, please contact Ascent Research.
